Kyverna Therapeutics (KYTX) Gains from Investment Securities (2023 - 2026)
Kyverna Therapeutics (KYTX) reported Gains from Investment Securities of $428182.0 for Q1 2026, down 37.74% on a YoY basis from $687679.0 in Q1 2025, and down 49.03% quarter-over-quarter from $840000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Kyverna Therapeutics has reported Gains from Investment Securities for 4 years, with the latest figure at $428182.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 37.74% year-over-year to $428182.0; the trailing twelve-month figure through Mar 2026 stood at $428182.0 (down 37.74% YoY), and the FY2025 full-year result was $9.3 million, up 22.84% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $428182.0, down from $840000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $4.2 million in Q1 2024, with the low at $100000.0 in Q3 2023.
- Historically, Gains from Investment Securities has averaged $1.0 million across 4 years, with a median of $443662.5 in 2024.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities jumped 2417.09% — and 2025, when it slumped 83.74%.
- Kyverna Therapeutics' Gains from Investment Securities stood at $581000.0 in 2023, then tumbled by 48.36% to $300000.0 in 2024, then jumped by 180.0% to $840000.0 in 2025, then slumped by 49.03% to $428182.0 in 2026.
- The last three Gains from Investment Securities figures came in at $428182.0 (Q1 2026), $840000.0 (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Kyverna Therapeutics | 492.54 Mn | 259.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 428,182.00 |
| Mar 31, 2026 | 428,182.00 |
| Dec 31, 2025 | 840,000.00 |
| Dec 31, 2025 | 840,000.00 |
| Sep 30, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Mar 31, 2025 | 687,679.00 |
| Mar 31, 2025 | 687,679.00 |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 459,143.00 |
| Sep 30, 2024 | 459,143.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 4.23 Mn |
| Mar 31, 2024 | 4.23 Mn |
| Dec 31, 2023 | 581,000.00 |
| Dec 31, 2023 | 581,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Sep 30, 2023 | 100,000.00 |